- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thal...
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Corten Capital and Ampersand Capital Partners (“Ampersand”) are pleased to announce the completion of their acquisition of Beacon Intelligenc...
Further expansion of the existing strategic partnership reflects continued high demand for Lonza’s high-quality global biologics outsourcing de...
Advancement of commercial-ready formulation supports scalability and late-stage development Aspen Neuroscience, Inc., a clinical-stage regenerative medi...
Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, announced that it h...
Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company develo...
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), me...
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery...
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing pl...
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, announced that the California Institute for Regenerative Medicine (C...
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physi...
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of He...
© 2026 Biopharma Boardroom. All Rights Reserved.
